desflurane

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,STK33,TEK,TTK	29
kinase-selectivity-class	PDK1,PDK2	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	143.51	41.37	42	1450	31575	90595380
Hyperthermia malignant	96.66	41.37	17	1475	1281	90625674
Procedural hypotension	93.11	41.37	17	1475	1583	90625372
Bradycardia	89.81	41.37	38	1454	83809	90543146
Serotonin syndrome	87.11	41.37	30	1462	37857	90589098
Neuromuscular block prolonged	86.50	41.37	14	1478	638	90626317
Vocal cord dysfunction	81.78	41.37	14	1478	900	90626055
Cardiac arrest	81.63	41.37	38	1454	104897	90522058
Delayed recovery from anaesthesia	66.81	41.37	12	1480	1018	90625937
Anaphylactic reaction	56.75	41.37	28	1464	87496	90539459
Drug interaction	56.36	41.37	42	1450	276411	90350544
Bronchospasm	49.89	41.37	17	1475	20692	90606263
Vitamin K deficiency	46.98	41.37	8	1484	497	90626458
Respiratory depression	42.32	41.37	14	1478	15561	90611394
Unwanted awareness during anaesthesia	41.63	41.37	7	1485	403	90626552

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	190.20	41.52	37	1262	2621	42617415
Anaphylactic shock	110.16	41.52	37	1262	23480	42596556
Serotonin syndrome	83.99	41.52	31	1268	25814	42594222
Seizure like phenomena	82.86	41.52	16	1283	1081	42618955
Bronchospasm	71.21	41.52	23	1276	12862	42607174
Neuromuscular block prolonged	59.12	41.52	11	1288	608	42619428
Trigemino-cardiac reflex	51.16	41.52	9	1290	362	42619674
Hypotension	51.11	41.52	50	1249	257581	42362455
Anticholinergic syndrome	43.39	41.52	10	1289	1579	42618457
Cardiac arrest	41.77	41.52	31	1268	109289	42510747

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	271.87	37.76	52	2889	3848	110582510
Anaphylactic shock	231.49	37.76	76	2865	51470	110534888
Serotonin syndrome	164.31	37.76	61	2880	59092	110527266
Neuromuscular block prolonged	140.77	37.76	25	2916	1222	110585136
Bronchospasm	113.43	37.76	39	2902	30200	110556158
Bradycardia	107.85	37.76	61	2880	155456	110430902
Cardiac arrest	107.16	37.76	66	2875	196687	110389671
Delayed recovery from anaesthesia	102.54	37.76	21	2920	2194	110584164
Post procedural complication	94.62	37.76	33	2908	26625	110559733
Drug interaction	83.11	37.76	83	2858	500100	110086258
Procedural hypotension	82.91	37.76	18	2923	2487	110583871
Anaphylactic reaction	79.61	37.76	45	2896	114255	110472103
Hypotension	78.08	37.76	82	2859	523767	110062591
Circulatory collapse	75.92	37.76	32	2909	42961	110543397
Vocal cord dysfunction	74.50	37.76	14	2927	936	110585422
Seizure like phenomena	72.22	37.76	16	2925	2425	110583933
Trigemino-cardiac reflex	63.59	37.76	11	2930	460	110585898
Anticholinergic syndrome	58.37	37.76	15	2926	4265	110582093
Laryngospasm	57.08	37.76	15	2926	4653	110581705
Recurrence of neuromuscular blockade	51.02	37.76	9	2932	422	110585936
Ventricular tachycardia	46.85	37.76	24	2917	49985	110536373
Unwanted awareness during anaesthesia	44.83	37.76	8	2933	401	110585957
Blood pressure decreased	43.97	37.76	31	2910	115060	110471298
Tachycardia	40.04	37.76	39	2902	226606	110359752
Vitamin K deficiency	38.35	37.76	8	2933	913	110585445
Respiratory depression	37.83	37.76	18	2923	31983	110554375

Source	Code	Description
ATC	N01AB07	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons
MeSH PA	D000777	Anesthetics
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018685	Anesthetics, Inhalation
CHEBI has role	CHEBI:38870	inhalation anaesthetic
FDA EPC	N0000175681	General Anesthetic
FDA PE	N0000175975	General Anesthesia

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

desflurane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Hyperkalemia	contraindication	14140009
Cirrhosis of liver	contraindication	19943007	DOID:5082
Viral hepatitis C	contraindication	50711007	DOID:1883
Viral hepatitis type B	contraindication	66071002	DOID:2043
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Myasthenia gravis	contraindication	91637004	DOID:437
Disease of liver	contraindication	235856003	DOID:409
Neuromyopathy	contraindication	255522009	DOID:440
Familial periodic paralysis	contraindication	267607008	DOID:1029
Lesion of brain	contraindication	301766008
Malignant hyperthermia	contraindication	405501007
Disorder of coronary artery	contraindication	414024009

Target	Class	Pharos	UniProt	Action	Bioact source	MoA source
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 3	Ion channel	O14649	KCNK3_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 9	Ion channel	Q9NPC2	KCNK9_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 10	Ion channel	P57789	KCNKA_HUMAN	OPENER	CHEMBL	CHEMBL
Potassium channel subfamily K member 18	Ion channel	Q7Z418	KCNKI_HUMAN	OPENER	CHEMBL	CHEMBL
Glycine receptor (alpha-1/beta)	Ion channel	P23415 P48167	GLRA1_HUMAN GLRB_HUMAN	POSITIVE MODULATOR	CHEMBL	CHEMBL
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRP_HUMAN GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRE_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN GBRT_HUMAN	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	CHEMBL

ID	Source
4020649	VUID
N0000148295	NUI
D00546	KEGG_DRUG
27340	RXNORM
4020649	VANDF
C0063252	UMLSCUI
CHEBI:4445	CHEBI
DSF	PDB_CHEM_ID
CHEMBL1200733	ChEMBL_ID
DB01189	DRUGBANK_ID
D000077335	MESH_DESCRIPTOR_UI
42113	PUBCHEM_CID
6505	INN_ID
7156	IUPHAR_LIGAND_ID
CRS35BZ94Q	UNII
247482	MMSL
399944	MMSL
4545	MMSL
d02374	MMSL
004114	NDDF
108393001	SNOMEDCT_US
386841003	SNOMEDCT_US

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9961	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	17 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9961	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	17 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6172	LIQUID	240 mL	RESPIRATORY (INHALATION)	ANDA	28 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	10019-644	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	28 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	10019-644	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	28 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-646	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	27 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-646	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	27 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	66794-021	LIQUID	250 mL	RESPIRATORY (INHALATION)	unapproved drug other	18 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	66794-021	LIQUID	250 mL	RESPIRATORY (INHALATION)	unapproved drug other	18 sections